Guzman M, Molpeceres J, Garcia F, Aberturas M R
Dpto. Farmacia y Tecnologia Farmaceutica, Universidad de Alcala de Henares, Madrid, Spain.
J Microencapsul. 1996 Jan-Feb;13(1):25-39. doi: 10.3109/02652049609006801.
Ketoprofen was encapsulated within poly-epsilon-caprolactone (PCL) and hydroxypropyl methylcellulose phthalate 50 (HPMCP50) microspheres (MS). Scanning electron microscopy (SEM) studies showed spherical particles without surface crystal formation and differential scanning calorimetry (DSC) supported these results. MS of PCL or HPMCP50 had a mean particle size of 10.7 +/- 2.2 and 10.9 +/- 2.0 mu m respectively, whereas a mixture of these polymers increased the MS particle size to 30 mu m. Greater incorporation efficiencies were found for HPMCP50 MS (98.1 +/- 0.7). MS of PCL and HPMCP50 mixtures showed a decreased drug entrapment as the amount of PCL was increased (96.0 +/- 0.2 for 25% PCL, 95.6 +/- 1.8 for 50% PCL, 80.2 +/- 0.7 for 75% PCL and 78.9 +/- 9.0 for 100% PCL). Size exclusion chromatography (SEC) studies revealed a weak interaction between ketoprofen and PCL and some polymer degradation was found during HPMCP50 MS storage, probably by breaking of the phthalic anhydride bond to be anyhydroglucose backbone. Four types of cryoprotectors (glucose, trehalose, mannitol and sorbitol, at 5 and 10% W/V) and two freezing conditions (-196 and -20 degrees C) were evaluated in freeze-drying studies. For HPMCP50, the sizes of MS after reconstitution of liophylizates were nearly the same as the initial ones. For PCL MS only, those formulations with sorbitol or glucose at 10% and frozen at -196 degrees C showed acceptable results. In contrast to the rapid release rate of ketoprofen from PCL MS as a result of carrier porosity (80% released within 15 min), the release from HPMCP50 MS could be controlled by means of pH (40% released in the first 15 min in simulated gastric fluid and nearly 100% ketoprofen delivered in the same time in simulated intestinal fluid).
酮洛芬被包裹在聚ε-己内酯(PCL)和羟丙基甲基纤维素邻苯二甲酸酯50(HPMCP50)微球(MS)中。扫描电子显微镜(SEM)研究显示颗粒呈球形,无表面晶体形成,差示扫描量热法(DSC)支持了这些结果。PCL或HPMCP50的微球平均粒径分别为10.7±2.2和10.9±2.0μm,而这些聚合物的混合物使微球粒径增加到30μm。发现HPMCP50微球的包封效率更高(98.1±0.7)。随着PCL用量的增加,PCL与HPMCP50混合物的微球药物包封率降低(25%PCL时为96.0±0.2,50%PCL时为95.6±1.8,75%PCL时为80.2±0.7,100%PCL时为78.9±9.0)。尺寸排阻色谱(SEC)研究表明酮洛芬与PCL之间存在弱相互作用,并且在HPMCP50微球储存期间发现了一些聚合物降解,可能是由于邻苯二甲酸酐键断裂与脱水葡萄糖主链相连。在冷冻干燥研究中评估了四种类型的冷冻保护剂(葡萄糖、海藻糖、甘露醇和山梨醇,浓度为5%和10%W/V)和两种冷冻条件(-196℃和-20℃)。对于HPMCP50,冻干制品复溶后的微球尺寸与初始尺寸几乎相同。仅对于PCL微球,那些含有10%山梨醇或葡萄糖并在-196℃冷冻的制剂显示出可接受的结果。与由于载体孔隙率导致酮洛芬从PCL微球中快速释放(15分钟内释放80%)相反,HPMCP50微球的释放可以通过pH值来控制(在模拟胃液中前15分钟释放40%,在模拟肠液中相同时间内几乎释放100%的酮洛芬)。